The Global Programme to Eliminate Lymphatic Filariasis: Health Impact after 8 Years by Ottesen, Eric A. et al.
The Global Programme to Eliminate Lymphatic Filariasis:
Health Impact after 8 Years
Eric A. Ottesen




1Lymphatic Filariasis Support Center, Task Force for Child Survival and Development, Decatur, Georgia, United States of America, 2Global Community Partnerships,
GlaxoSmithKline, Brentford, United Kingdom, 3Preventive Chemotherapy and Transmission Control, World Health Organization, Geneva, Switzerland
Abstract
Background: In its first 8 years, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) achieved an
unprecedentedly rapid scale-up: .1.9 billion treatments with anti-filarial drugs (albendazole, ivermectin, and
diethylcarbamazine) were provided via yearly mass drug administration (MDA) to a minimum of 570 million individuals
living in 48 of the 83 initially identified LF-endemic countries.
Methodology: To assess the health impact that this massive global effort has had, we analyzed the benefits accrued first
from preventing or stopping the progression of LF disease, and then from the broader anti-parasite effects (‘beyond-LF’
benefits) attributable to the use of albendazole and ivermectin. Projections were based on demographic and disease
prevalence data from publications of the Population Reference Bureau, The World Bank, and the World Health Organization.
Result: Between 2000 and 2007, the GPELF prevented LF disease in an estimated 6.6 million newborns who would
otherwise have acquired LF, thus averting in their lifetimes nearly 1.4 million cases of hydrocele, 800,000 cases of
lymphedema and 4.4 million cases of subclinical disease. Similarly, 9.5 million individuals—previously infected but without
overt manifestations of disease—were protected from developing hydrocele (6.0 million) or lymphedema (3.5 million).
These LF-related benefits, by themselves, translate into 32 million DALYs (Disability Adjusted Life Years) averted. Ancillary,
‘beyond-LF’ benefits from the .1.9 billion treatments delivered by the GPELF were also enormous, especially because of the
.310 million treatments to the children and women of childbearing age who received albendazole with/without ivermectin
(effectively treating intestinal helminths, onchocerciasis, lice, scabies, and other conditions). These benefits can be described
but remain difficult to quantify, largely because of the poorly defined epidemiology of these latter infections.
Conclusion: The GPELF has earlier been described as a ‘best buy’ in global health; this present tally of attributable health
benefits from its first 8 years strengthens this notion considerably.
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Introduction
In 1997, the Global Programme to Eliminate Lymphatic
Filariasis (GPELF) was created in response to a specific resolution
by the World Health Assembly [1]. At that time the World health
Organization (WHO), having recently devised a strategy aimed at
achieving LF elimination through ‘mass drug administration’
(MDA) [2], received extraordinary pledges from two pharmaceu-
tical companies (GlaxoSmithKline and Merck & Co., Inc.) for
long-term drug donations of unprecedented size to jumpstart this
nascent program.
The impressive programmatic progress made by the GPELF has
been documentedinanumberofvaluablereviewsandupdates[1,3–
7]; however, what is most needed now – for donors who are
supporting thiseffort,for theMinistries of Health and healthworkers
who are laboring on its behalf and for endemic communities who
continue to investtheir energies and resources towards itssuccess – is
tounderstandnot justthe technicalachievements,butespeciallywhat
difference it all has made to the health and welfare of the at-risk
populations. What impact has 10 years of focus on LF – long
recognizedasoneofthemostdebilitatingandeconomically-draining
of the neglected tropical diseases – really had?
To answer this question requires not just a tabulation of the
GPELF’s programmatic achievements in providing necessary
drugs to the targeted at-risk populations, but also, importantly, a
projection of the public health gain from this effort, using estimates




Specific sources for the data are identified as they are presented;
in general, however:
1) Numbers related to LF endemicity, populations at-risk
(Table 1) and treatments delivered were derived from
publications by WHO in the Weekly Epidemiological Record
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[4–10]; this information is also recorded at www.who.int/
lymphatic_filariasis.
2) Information on the quantities of albendazole, ivermectin
(Mectizan) and diethylcarbamazine (DEC) used in the
GPELF came from these same WER reports [4–7], from
WHO’s Annual Reports (available at www.who.int/
lymphatic_filariasis) and from records of GlaxoSmithKline
and the Mectizan Donation Program.
3) Population demographic figures used to calculate age or
gender subpopulations of the total at-risk populations were
taken from the Population Reference Bureau [11] and the
World Bank Health, Nutrition and Population Statistics
[12].
4) Disability weights and formulas for calculating Disability
Adjusted Life Years (DALYs) were derived from the Global
Burden of Disease [13].
5) Information on the clinical profiles and the effectiveness of
treatment for both LF and soil transmitted helminth (STH)
infections has been taken from scientific publications [3,14–
16].
6) Estimates of the epidemiology of STH infections (number
and distribution of affected individuals worldwide) came
from published information [17].
Impact Projections
The assumptions made and the rationale behind the projections
are outlined below and summarized in Tables 2 and 3.
Impact estimates: LF-related. Babies protected from infection.
To estimate the number of babies born into LF treatment areas
between 2000 and 2007, demographic data from each country
(births per 1,000 population discounted by infant mortality rates
[18] were applied to those populations living in areas targeted for
LF treatments. Since LF transmission might not stop immediately
after MDAs begin, changes observed in mosquito infection rates
post MDA were used to estimate changes in LF transmission as
progressively decreasing to 50%, 25%, 12%, 6%, and 0% of pre-
MDA levels after each of the first 5 MDAs. These multipliers were
used on a country-by-country and MDA-by-MDA basis to
discount the number of surviving babies born into MDA areas,
thereby allowing an estimate of the number of newborns protected
from potential LF infection (66 million). Since LF infections are
estimated to occur in approximately 10% of the at-risk population
[3], 6.6 million newborn babies are therefore considered protected
from contracting LF.
Cases of morbidity prevented in newborns. Globally, 12.5% of LF
infections are estimated to result in lymphedema, 20.8% in
hydrocele and the remainder, 66.7%, in subclinical disease [3].
Cases of disease averted (hydrocele, lymphedema and subclinical)
were calculated by multiplying these proportions by the number of
LF infections averted in babies.
DALYs averted in newborns. The number of DALYs averted in
newborns was calculated using methods outlined in Global Burden of
Disease, utilizing disability weights, the number of cases of clinical
disease averted (hydrocele and lymphedema), an estimated onset
of disease at age 20 and region-specific life spans [13]. Since
disability weights are not available for subclinical LF disease,
DALYs associated with this manifestation were not estimated.
For all of the calculations associated with the prevention of LF
disease, it was assumed, based on available information, that treated
individuals will not become re-infected in the context of
diminished LF transmission in MDA-covered areas.
Infected individuals protected from progression of subclinical disease to
clinical disease. For each country the number of individuals treated
in each MDA is known, but since it is not known how many
unique individuals have received treatment in a program with
multiple MDAs, the conservative approach to identifying this
number of unique individuals treated in any one country is to
identify the maximal numbers of individuals treated in any single
MDA for each country. These numbers were then summed for all
countries and used as the minimum total number of individuals
already treated (570 million). Since LF infections are estimated to
occur in approximately 10% of the at-risk population [3], 57
million would be expected to be infected with LF. Approximately
two-thirds of infected individuals have subclinical disease [3] (38
million), with 50% of those expected to progress to overt disease (19
million). Approximately 62.5% of individuals with overt disease
manifest hydrocele (11.9 million) and 37.5% manifest lymphede-
ma (7.1 million). If it is assumed that treatment halts disease
progression in only 50% of subclinical cases (a conservative
estimate [19]), 9.5 million people would have been protected











Africa (AFRO) 39 394 176
Americas (AMRO) 7 8.87 3.39
Eastern Mediterranean (EMRO) 3 14.9 6.50
South-east Asia (SEARO) 9 851 297
Western Pacific (WPRO) 25 31.6 11.1
TOTAL: 83 1,300 494
doi:10.1371/journal.pntd.0000317.t001
Author Summary
Lymphatic filariasis (LF) is a vector-borne, chronically
disabling parasitic infection causing elephantiasis, lymph-
edema, and hydrocele. The infection is endemic in 83
countries worldwide, with more than 1.2 billion people at
risk and 120 million already infected. Since 1998, the
Global Programme to Eliminate Lymphatic Filariasis
(GPELF) has targeted elimination of LF by 2020. In its first
8 operational years, the program has scaled-up to provide
more than 1.9 billion treatments through annual, single-
dose mass drug administration (MDA) to ,570 million
individuals living in 48 LF-endemic countries. Not only do
the GPELF drugs prevent the spread of LF, they also stop
the progression of disease in those already infected. In
addition, since two of the three drugs used for LF
elimination have broad anti-parasite properties, treated
populations are freed from both intestinal worms and from
skin infections with onchocerca, lice, and scabies. To better
understand the public health benefit of this ongoing
global health initiative, we undertook an analysis of
Programme data made available to WHO by participating
countries. Our conservative estimates show that the GPELF
has had an unprecedented public health impact on both
LF and other neglected tropical diseases; it justly deserves
the accolade of ‘a best buy’ in global health.
Global Programme to Eliminate LF: Health Impact
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3.5 million cases of lymphedema averted).
DALYs averted through halting progression of disease. The number of
DALYs averted through progression of disease was calculated using
methods outlined in Global Burden of Disease, utilizing disability
weights, the number of cases of clinical disease averted (hydrocele
and lymphedema; calculated as described above), an estimated onset
of disease at age 20 and region-specific life spans [13].
Impact estimates: ‘Beyond-LF’ benefits. Because
individual country estimates of the prevalence and distribution
of soil transmitted helminthiases are generally not available, it was
not possible to estimate directly the number of STH infections,
either in children or women of child bearing age, that have been
treated as a consequence of LF MDA activities. However, since it
is widely accepted that the common STH infections are distributed
throughout the pan-tropical belt where lymphatic filariasis is
endemic [17], we recognize that a proportion of the albendazole
and ivermectin treatments delivered for LF will have had a
beneficial impact for children and women of child bearing age
who harbor intestinal helminth infections. The number of
individual children less than 15 years of age treated with
albendazole was estimated by multiplying demographic data
(children under the age of 15 years, for each country [11] by that
country’s total treatment figures, then summing the maximal
number of children treated in any single MDA for each country
between 2000 and 2007 (the conservative estimate of the number
of unique individuals treated; see above). Since age is an exclusion
criterion for LF treatment, the annual estimates thus derived were
discounted depending on the therapeutic regimen applied as
follows: in ivermectin and albendazole areas of Africa and the
Yemen, data for children 5 to 15 years of age only are included,
whereas for the rest of the world where DEC and albendazole are
utilized, data for children 3 to 15 years of age are included.
Women between 15 and 49 years were considered to be of
childbearing age, and the number of individuals treated in this age
class was calculated by multiplying demographic data [11] for
each country by that country’s total treatment figures, then
summing the maximal number treated in any single MDA for each
country between 2000 and 2007 (the conservative estimate of the
number of unique individuals treated; see above). Since pregnancy
is an exclusion criterion for LF treatment, the annual estimates
thus derived were discounted by subtracting the estimated percent
of the female population that is pregnant at any given time: the
total fertility rate for each region was multiplied by a nine month
gestational period and divided by 408 months (representing the
estimated average number of reproductive months in a woman’s
lifetime).
Whilst the beneficial outcomes of treating STH infections in
these population groups are listed, we do not attempt to quantify the
accumulated health impact because of the uncertainty surround-
ing the prevalence estimates. The same rationale and argument
adopted for soil transmitted helminth infections were applied when
we considered the impact of ivermectin treatments on skin diseases
of various etiology in Africa.
Table 2. Projected Health Impact – LF Related.
Impact #1 Individuals Protected Disease Prevented DALYs Averted
6.6 million newborns 1.4 million cases of hydrocele 3.2 million DALYs
800,000 cases of lymphedema 2.8 million DALYs
4.4 million cases of subclinical disease ?
Assumptions and Reasoning
1) 66 million babies born into at-risk areas under MDA 2000–2007 (discounted for infant mortality) [11]
2) LF infections occur in 10% of at-risk population [3]
3) 12.5% of LF infections result in lymphedema, 20.8% in hydrocele, 66.7% in subclinical damage [3]
4) Disability weights (based on Global Burden of Disease methods): 0.105 for lymphedema, 0.073 for hydrocele; onset at age 20; life span is
Region-specific
5) LF transmission (estimated by mosquito infection rates) falls progressively to 50%, 25%, 12%, 6%, and 0% pre-MDA levels after each of the first
5 MDAs, respectively
Impact #2 Individuals Protected Disease Prevented DALYs Averted
9.5 million people 6.0 million cases of hydrocele 14 million DALYs
3.5 million cases of lymphedema 12 million DALYs
Assumptions and Reasoning
1) 570 million individuals (at minimum) treated under MDAs 2000–2007. The maximal number of individuals treated in any single MDA was
determined for each country. The sum of these numbers indicates the minimum total number of individuals treated.
2) LF infections occur in 10% of at-risk (i.e., treated) population [3] (here 57 million) with 1/3 having clinical manifestations and 2/3 having
subclinical disease [3] (here 38 million)
3) To maintain this 1/3:2/3 ratio 50% of those with subclinical disease must progress to overt disease (62.5% manifesting hydrocele [11.9 million]
and 37.5%, lymphedema [7.1 million]) [3]
4) If treatment halts progression in only 50% of the subclinical cases (a conservative estimate [19]), 9.5 million people would have been
protected from developing overt disease (6 million hydrocele; 3.5 million lymphedema)
5) Disability weights**: 0.105 for lymphedema, 0.073 for hydrocele; onset at age 20; life span, Region-specific
6) Treated individuals will not become re-infected in context of diminished LF transmission in MDA-covered areas
doi:10.1371/journal.pntd.0000317.t002
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Programmatic achievements of the GPELF 2000–2007
1. The Global Programme. One hundred twenty million
people are affected with LF – 40 million with limb or genital
damage recognized as either lymphedema/elephantiasis (15
million) or hydrocele (25 million), and twice that number with
subclinical disease principally of the lymphatics or kidneys [3].
These 120 million people live in 83 endemic countries of the
tropics and subtropics where 1.3 billion people (1/5 of the world’s
population) comprise the total population considered ‘at risk’ for
infection through their exposure to LF’s mosquito-borne infective
larvae (Table 1) [5]. More than a third of these are children [11].
Little more than a decade ago it was established that single
doses of a 2-drug regimen (either albendazole+ivermectin or
albendazole+DEC) can effectively eliminate microfilariae from the
blood of infected individuals for periods often in excess of a year
[20]. Once understood, this drug effectiveness permitted develop-
ment of a strategy for LF elimination based on treating entire at-risk
populations yearly with one of these two safe, effective 2-drug
regimens in order to reduce microfilaremia (MF) below a
‘transmission threshold’ where future recrudescence would be
unlikely even after population treatment was halted. From
estimates of the life span of the adult parasites (Wuchereria bancrofti
or Brugia malayi), from projections of the levels of ‘drug coverage’
that must be achieved in the targeted populations and from earlier
experiences in countries targeting LF elimination, the average
number of rounds of effectively conducted, yearly ‘mass drug
administrations’ (MDAs) necessary to achieve success for national
programs was estimated to be 4–6 [2]. Recent experience from
both program observations and specific research studies is
consistent with this notion that in most instances between 2 and
6 rounds of effective MDA are able to clear microfilaremia (see
below for sentinel site data). There are, however, specific situations
where more than 6 rounds might be required, since the number of
MDAs necessary appears to depend principally on the pre-
treatment microfilaremia levels, programmatic drug ‘coverage’
and local vector parasite complex [21].
2. Treatments delivered. Since its official inauguration in
2000 the GPELF has seen the most rapid expansion of any drug
delivery program in public health history; by the end of 2007 more
than 1.9 billion treatments for LF had been delivered [7], almost L
by the program in India (initially a program based on DEC alone;
more recently, on albendazole+DEC) with the remainder
Table 3. Projected Health Impact – Beyond LF.
Impact #3 Individuals Reached Target Health Benefits
56.6 million children
-minimal estimate-
Soil-transmitted helminthes (intestinal parasites:
hookworm, roundworm, whipworm)
Weight/height gain, learning ability, cognitive testing,
school attendance, fitness, activity [14,26–28]
Assumptions and Reasoning
1) 172 million treatments of albendazole given to children (age 2–15 in countries treated with DEC+albendazole; 5–15 in countries using
ivermectin+albendazole) in 48 countries during MDAs 2000–2007 [4–7].
2) The maximal number of children treated in any single MDA was determined for each country. The sum of these numbers indicates the minimum
total number of children treated (56.6 million) [4–7].
3) Uncertainty of STH prevalence estimates limits the specific quantification of health benefits despite their description in published studies [14,26–
28].
Impact #4 Individuals Reached Target Health Benefits
44.5 million women of childbearing
age (not pregnant)
-minimal estimate-
Soil-transmitted helminthes (intestinal parasites:
hookworm, roundworm, whipworm)
Decreased anemia [16], maternal mortality, infant
mortality; increased infant birth-weight [29]
Assumptions and Reasoning
1) 140 million treatments of albendazole given to non-pregnant women-of-childbearing-age (15–49 years old) in 48 countries during MDAs 2000–
2007 [4–7,12].
2) The maximal number of such women treated in any single MDA was determined for each country [4–7]. The sum of these numbers indicates the
minimum total number of women-of-childbearing-age treated (44.5 million).
3) Uncertainty of STH prevalence estimates limits the specific quantification of health benefits despite their description in published studies
[16,27,30].
Impact #5 Individuals Reached Target Health Benefits
45 million people in Africa
-minimal estimate-
Onchocerciasis, scabies, lice Decreased physical, mental discomfort (severe itching)
[32]; prevention of renal complications of streptococcal
superinfections [35]
Assumptions and Reasoning
1) 149 million treatments of ivermectin given to communities in 12 African countries during MDAs 2000–2007 [4–7].
2) The maximal number of individuals treated in any single MDA was determined for each country. The sum of these numbers indicates the minimum
total number of individuals treated (45 million) [4–7].
3) Uncertainty of prevalence estimates for each of these conditions limits the specific calculation of health benefits despite the descriptions reported
in published studies [32–34].
doi:10.1371/journal.pntd.0000317.t003
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(Fig 1). The amount of drug donated to support this Programme has
been extraordinary: more than 740 million tablets of albendazole
and more than 590 million tablets of ivermectin were provided
between 2000–2007 by the Global Programme’s partners in the
pharmaceutical industry. The amount of the non-donated drug
(DEC)thathadtobepurchasedduringthissameperiod bycountries
that utilize DEC instead of ivermectin (which is used for LF only in
Africa [3]) was more than 4.7 billion tablets (Fig 2A & B).
3. Programme effectiveness in decreasing LF
prevalence. The effectiveness of GPELF’s strategy to reduce
the prevalence of microfilaremia in an endemic population to
levels below that believed necessary to sustain the parasite’s life
cycle has been substantiated by research teams in well-controlled,
large-scale initiatives (e.g. in Egypt [22] and Papua New Guinea
[23]). In addition, assessment of programmatically collected data
available to WHO from another 20 countries shows similar
progressive declines in mf prevalence in treated communities
(Fig. 3), with greater than 10-fold reduction in mf-prevalence levels
seen in sentinel-site communities that have received 6 rounds of
MDA and total clearance of mf (by inference, interruption of LF
transmission) recorded in almost 2/3 of the communities after 5
MDA rounds (Fig. 4).
Health impact of the GPELF 2000–2007
As impressive as the record is for the number of treatments
given, the number of albendazole and ivermectin tablets donated,
the amount of DEC purchased, and the number of communities
cleared of microfilaremia during the first 8 years of this Global
Programme, still the most important Programme outcome is the
overall health benefit that the GPELF has brought to populations
at-risk for LF. This benefit must derive from projections based on the
best data and most reasonable assumptions available (see below
and Tables 2 & 3 for the assumptions and implications).
There are two principal sources of this health benefit:
1. LF-related benefits – i.e., those coming directly from the effects
of the MDAs in preventing the acquisition of lymphatic filarial
disease or in arresting its progression
2. ‘Beyond-LF’ benefits – i.e., those coming from ancillary benefits
of the highly effective, broad-spectrum anti-parasitic drugs,
albendazole and ivermectin, used in the Programme.
1. Projected health impact that is LF-related. Protecting
newborns from LF infection and disease. Since MDAs, by decreasing and
then stopping LF transmission, will prevent uninfected individuals
from becoming infected, the clearest measure of the Programme’s
Figure 1. Cumulative treatments in GPELF. Progressive increase in number of treatments given through 2007; distribution by WHO region is
depicted in pie-chart.
doi:10.1371/journal.pntd.0000317.g001
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the lifetime of babies born into areas where their likelihood of
acquiring infection has become much diminished or nil. To
determine this impact requires an understanding of the number of
babies born (and surviving) in areas covered by LF MDAs, the
number who would have acquired infection (and disease) in the
absence of GPELF, the ‘disability weights’ for different
manifestations of LF disease and the rate at which exposure to
LF infection declines in treated populations. When these variables
were assessed [see Discussion and Table 2 for fuller description],
the following conclusions could be made:
N Impact #1 - Prevention of LF infection (and disease):
Between 2000–2007, 6.6 million newborns (the fraction of all newborns
who would have been expected to acquire LF) were protected by GPELF –
thereby averting in their lifetimes nearly 1.4 million cases of hydrocele,
more than 800,000 cases of lymphedema and 4.4 million cases of
subclinical disease (Table 2).
# Because of this disease prevention, 6.0 million Disability Adjusted Life
Years (DALYs) have been averted (3.2 million from prevention of
hydrocele and 2.8 million from prevention of lymphedema [Table 2]).
Preventing the progression to overt disease in LF-endemic populations. With
evidence now available that the MDA treatment regimens for LF
can halt, or even reverse, the progression of subclinical to overt
disease [19,24,25], it is clear that those already infected but having
no overt disease also benefit directly from the yearly MDAs. To
quantify this benefit requires understanding the number of
individuals treated during the MDAs, the proportion of these
individuals with subclinical LF disease, the number who would
have progressed to each of the manifestations of LF disease and
the ‘disability weights’ for each of these manifestations. When all of
these were considered (see Discussion and Table 2), the following
could be recognized:
N Impact #2 - Prevention of LF disease: Between 2000–
2007, 9.5 million individuals – previously infected but without overt
manifestations of disease – were protected by GPELF from developing
hydrocele (6.0 million) or lymphedema 3.5 million).
# This disease prevention translates into 26 million DALYs averted (14
million from hydrocele prevention and 12 million from lymphedema
prevention).
2. Projected health impact from ‘Beyond-LF’
benefits. Preventing the consequences of intestinal parasite infections.
The best drugs to control intestinal parasites (i.e., ‘soil-transmitted
helminths’ [STH]: hookworm, roundworm and whipworm) are
the same drugs (albendazole and ivermectin) used to eliminate LF
Figure 2. Cumulative totals of donated drugs (Panel A), albendazole and ivermectin (Mectizan), and purchased drug (Panel B) DEC,
used in GPELF between 2000 and 2007.
doi:10.1371/journal.pntd.0000317.g002
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approval only for lymphatic filariasis and onchocerciasis and is
donated by Merck & Co., Inc. only for those indications, each year
millions of children and women-of-childbearing-age are
concomitantly treated for debilitating intestinal parasite infections
(without additional cost or effort) while participating in their
national programs to eliminate LF. To identify the impact of such
treatment requires estimation of the number of children and the
number of women-of-childbearing-age who received albendazole
(with or without ivermectin) in all GPELF countries. Thus,
N Impact #3 - ‘Beyond-LF’ benefit for children with
intestinal parasites: Between 2000–2007, more than 172
million treatments for intestinal parasite infections were given to 56.6
million children by GPELF (Table 3)
# Based on earlier research studies, each infected child receiving treatment
would be expected to develop increased appetite [26] (leading, in some
settings, to 1 kg of extra weight gain and 0.6 cm extra growth in the
first 5 months) [27]; greater eye-hand coordination, learning ability and
concentration [14]; better school attendance, cognitive testing (20%
improvement) [28], fitness scores and spontaneous play activity (43%
increase) [26,27].
N Impact #4 - ‘Beyond-LF’ benefit for women-of-
childbearing-age with intestinal parasites: Between
2000–2007 more than 140 million treatments for STH were given to
44.5 million women-of-childbearing age by GPELF (Table 3).
# Repeated treatment of hookworm and other intestinal parasites improves
both nutritional status and, most importantly, iron stores in women
during their reproductive years [16,29]. Prior studies predict that such
treatment can lead to an increase in infant birth-weights by more than
50 grams and a drop in infant mortality by as much as 40% [29].
Maternal mortality should also decrease significantly in women
receiving GPELF treatments, since iron deficiency anemia is a
prominent cause of maternal mortality [30].
Prevention of debilitating skin diseases. Onchocerciasis, scabies, and
pediculosis (lice) are all diseases of the skin caused by parasites
common in resource poor communities and associated with
appreciable mental and physical disability in affected populations.
Ivermectin, one of the two drugs co-administered by the GPELF
in Africa, is the best oral treatment for all of these debilitating skin
diseases [31–33]; it is also the mainstay drug for onchocerciasis
control programs in Africa [34]. To gauge the GPELF impact on
skin diseases it is necessary first to understand the number of
Figure 3. Effect of MDA on microfilaremia prevalence. Individuals in all of the sentinel sites (approximately 500 persons per site) reporting to
the Global Programme were evaluated for microfilaremia. Progressive decline in prevalence among these individuals was recorded during yearly
assessments (n=131 sentinel sites for year 1; n=124 for year 2; n=139 for year 3; n=148 for year 4; n=68 for year 5; and n=12 for year 6).
doi:10.1371/journal.pntd.0000317.g003
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Africa. Thus,
N Impact #5 - ‘Beyond-LF’ benefit for people with skin
diseases in Africa: Between 2000–2007, over 149 million
treatments with ivermectin were administered by GPELF or APOC (African
Programme for Onchocerciasis Control) to more than 45 million people in
African communities (Table 3) where the prevalence of scabies skin infection
may exceed 30% and the prevalence of onchocerciasis even more.
# Ivermectin’s long lasting impact on scabies can cause community
prevalence to fall dramatically after 1 cycle of treatment and to
disappear almost completely after 2 or more treatments [31]. Cured
individuals show improvements in sleep patterns and overall wellbeing,
but also importantly, treatment of scabies in childhood can prevent the
post-streptococcal renal disease induced by group B streptococcus skin
infections that often complicate chronic scabies infection [35].
# Because of its broad geographic range, the GPELF has brought
ivermectin treatment to additional millions of people living in
onchocerciasis-endemic areas not previously targeted by onchocerciasis
control programs (as these programs focus only on communities where
the prevalence of onchocerciasis exceeds 40%) [34].
Discussion
Since WHO’s Global Programme to Eliminate Lymphatic
Filariasis was officially launched in 2000, its programmatic
achievements [recorded here through 2007] are unparalleled
(Box 1): 1.9 billion treatments delivered through yearly MDAs to
over 570 million people in 48 endemic countries. These
accomplishments were made possible by the enormous drug
donations of albendazole (over 740 million tablets from Glax-
oSmithKline through 2007) and ivermectin (over 590 million
tablets of Mectizan from Merck & Co., Inc.), by the willingness of
National Programs to procure 4.7 billion tablets of DEC, and by
the early support from numerous other organizations – most
significantly the Bill and Melinda Gates Foundation, the Arab
Fund for Economic and Social Development, the international
development agencies of Japan and the United Kingdom and the
Ministries of Health of endemic countries.
Though it is without question that this Programme has had a
very great impact on global health, quantifying this impact still
poses difficult challenges. Principally this is because all projections
must be made not just from the numbers of people treated but also
from the more-difficult-to-quantify effects of such treatment.
Assumptions derived from current best understanding must be
linked with the available data to formulate the health impact
projections, and while making such assumptions is never entirely
satisfactory, the present analysis does endeavor to identify clearly
both the assumptions themselves and the sources of the data used
to generate the projections; it also has chosen to err on the
conservative side in most estimations.
For the GPELF, health benefits lie in two domains: one related
to the Programme’s effects on lymphatic filarial disease and its
consequences, and the other related to the outcome of treating LF-
endemic populations with one or both of the very safe, broad-
Figure 4. Clearance of microfilaremia from each sentinel site (approximately 500 persons per site) reporting to the Global
Programme after 5 rounds of MDA treatment (n=68).
doi:10.1371/journal.pntd.0000317.g004
Global Programme to Eliminate LF: Health Impact
www.plosntds.org 8 October 2008 | Volume 2 | Issue 10 | e317spectrum anti-parasitic drugs used by the Programme, albendazole
and ivermectin.
LF-related impact
To gauge the LF-related impact, this analysis has considered
quantitatively only what has been accomplished by: 1) preventing
infection in those born into areas where GPELF is active and 2)
stopping the progression to clinical disease in previously infected
individuals whose disease has not yet expressed itself overtly.
1) To identify the amount of infection prevented, the number of
babies born in areas under LF MDAs between 2000–2007 who
survived infancy was first determined, by country [11,12].
Estimation of how many of these newborns would have acquired
LF during their lives and what manifestations they would have
developed was based on the global prevalence figures available for
LF and its clinical manifestations (Table 2) [3]. Calculation of the
DALYs attributable to that amount of disease during the lifetimes
of those newborns assumed that clinical expression of disease
(hydrocele and lymphedema) had its onset at an average age of 20
years and persisted throughout the life of the individual.
Since the risk of exposure of these infants to LF depends on the
level of local transmission, it is necessary to estimate the rate of
decline of transmission (here using vector infection in mosquitoes
as a surrogate for transmission) as MDA programs progress.
While programmatic evidence exists that effective transmission of
LF might cease very soon after the initiation of MDA activities
[22,23,36], entomologic studies linked with anti-filarial single-
dose treatment regimens indicate that the decline in vector infection
may be more gradual [22,23,37–41]. Since the availability of
such data is too limited (with respect to vector species, collection
techniques, parasite assessments, LF prevalence, treatment
regimens, and other variables) to give precise estimates of post-
MDA changes in vector infection, data from available studies
[22,23,37–41] were pooled, yielding a relationship that describes
an ‘average’ rate-of-decline of vector infection; namely, declines
to 50%, 25%, 12%, 6% and 0% of pre-treatment levels following
each of the first 5 MDAs, respectively. (As these numbers were
empirically defined, they already incorporate the influence of
population ‘coverage’ on MDA effectiveness.) This information
was then used to estimate the effect that each MDA had for each
treated population in each country in order to approximate the
exposure to LF in infants born after initiation of GPELF
activities.
2) Stopping the progression of subclinical to clinical disease in
those already infected contributes appreciably to the calculations
of LF-related health benefits from GPELF (Table 2). Evidence for
such effectiveness of MDA regimens in halting disease progression
is relatively recent and has focused particularly on children with
subclinical or early-stage lymphatic disease [19,25]. Because these
effects are just now being studied comprehensively, and in order to
be conservative in estimating GPELF’s health impact, the present
calculations are based on the conservative assumption [19] that
the MDA programs would arrest subclinical disease progression in
only 50% of the affected individuals (Table 2).
Though one cannot be completely certain of all of the
calculations in Table 2, it is still hard to escape the conclusion
that these values for GPELF’s LF-related health impact are almost
certainly gross underestimates – for at least 2 reasons. First, not
considered at all in the assessments of GPELF’s LF-prevention benefits
are those related to any of the manifestations of LF disease other
than hydrocele and lymphedema. Among those omitted, quanti-
tatively most important would be the Programme’s impact on
subclinical LF disease [24,25,42] – especially microfilaremia,
hematuria, lymphatic dilatation and lymphatic dysfunction –
which affect a very large percentage of those with LF infection [3]
but for which there are no ‘disability weights’ available for
calculating DALYs or DALYs averted. Also overlooked are other
extremely important, often debilitating overt clinical manifestations
of infection – especially, the very common, recurrent acute
adenolymphangitis episodes (ADL) and the progressive, crippling
pulmonary disease, tropical pulmonary eosinophilia (TPE) [3].
Excluding all of these important consequences of LF infection
from the calculations of GPELF’s health impact from preventing
LF ensures that these calculations will significantly underestimate
the Programme’s impact.
Second, none of these quantitative calculations of GPELF’s LF-
related health impact has taken into consideration the direct effect
that this Programme has had on arresting progression or
ameliorating clinical disease of affected individuals. In addition
to its delivery of essential anti-filarial drugs, the GPELF is also a
program that advocates and initiates ‘morbidity management’
activities based on vigorous personal hygiene management of
lymphedema or elephantiasis [43]. Dramatic improvement in both
physical state and mental attitude occurs in patients following the
hygiene guidelines [43,44], but none of the health impact of this
component of the GPELF has been quantified or captured in the
Box 1. The Global Programme to Eliminate LF – Its First 8 Years.
Reach Nearly 2 billion treatments delivered to more than 560 million people in 48 countries.
Dissemination More than 50% of endemic countries actively involved in annual MDA programmes.
Child Protection Nearly 176 million children already treated for LF, and over 66 million babies born into areas
now protected by MDA.
Public Health Impact on LF More than 6 million cases of hydrocele and 4 million cases of lymphoedema prevented,
translating into more than 32 million DALYs averted.
Additional Health Benefits More than 310 million treatments of albendazole delivered to women of child-bearing age
and school-age children, providing sustained relief from the negative consequences of soil-
transmitted helminth (STH) infections that include maternal anemia, low birth weight
newborns, excess infant mortality, inhibited growth and development, diminished
intellectual performance.
Almost 150 million treatments of ivermectin delivered to African communities, providing
sustained relief from onchocercal skin disease, scabies, lice and important STH infections.
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improvement in both lymphedema and hydrocele now being
reported by patients following MDA treatment alone (i.e., even in
the absence of hygiene management) [23].
‘Beyond-LF’ Health Impact
If the LF-related health impact of GPELF seems difficult to
quantify, the ‘beyond-LF’ impact presents an even greater
challenge. A major reason is that many of the ‘beyond LF’
benefits come from the impact that the GPELF drugs have on soil
transmitted helminth (STH) infections in the treated populations.
The quantitative epidemiology of these infections remains poorly
characterized, albeit for good reasons: not only are STH infections
caused by three distinct parasites (hookworm, roundworm and
whipworm), but these three infections also occur in unequal
proportions in different endemic regions and cause different
diseases with varying severity and health consequences. Further,
while the geographic overlap of STH infections with the LF at-risk
areas is felt to be almost universal [45], it is rarely known which
STH infections occur or with what abundance in which areas.
Thus, while general estimates of overall STH prevalence can be
approximated for areas where GPELF is active, the data itself is
not certain enough to be used quantitatively to project GPELF’s
health impact from treating STH infections.
Despite such limitations, a number of very important studies
have been carried out to document and measure the health
consequences of STH infections – usually by monitoring changes
in outcome indicators following treatment with albendazole or
other drugs. These have shown, for example, that
1) Soil transmitted helminth infections exact a severe toll on
the nutritional status and growth of infected children, but
intervention with albendazole and ivermectin can make an
extraordinary difference in their physical development, with
spectacular gains in growth parameters quantified in a
number of important studies [14–16,46,47].
2) Lethargy and lack of physical stamina often characterize
children infected with intestinal worms, but within weeks of
treatment significant increases can be found in physical
activity and spontaneous play. Resting heart rates, physical
fitness on the Harvard step test, and measurements of
spontaneous play behavior all improved in children from
Kenya and Indonesia after being treated for intestinal
worms [14,26,27,47].
3) Children infected with intestinal worms are frequently seen
to miss many more school days than their uninfected peers,
as documented in Jamaica where children with intense
Trichuris infections missed twice as many school days as
their infection-free peers [48]. Treatment leads to significant
reduction in school absenteeism; a 25% reduction was
recorded in Kenya following school-based treatment for
STH [49].
4) Children infected with intestinal worms perform poorly in
learning ability tests, cognitive function and educational
achievement, but treating school age children increases their
ability to learn, as documented by improvement in
children’s short and long term memory, executive function
language, problem solving and attention [50,51].
These STH infections that are treated by the GPELF MDAs are
not just important for children. While their effect on the health
and productivity of men remains poorly defined, in women-of-
childbearing-age hookworm infection is recognized as a major
cause of anemia, and this anemia significantly affects both
maternal and newborn morbidity and mortality. Indeed,
1) WHO estimates that women in developing countries may be
pregnant for half their reproductive lives and are at an
increased risk of anemia during this time [30].
2) Anemia in pregnancy has been clearly associated with poor
birth outcome, including low birth-weight [52–55] and
increased maternal morbidity and mortality [30,56,57].
3) Hookworm-attributable anemia, induced by deficiencies in
iron, protein and total energy, is a significant cause of
intrauterine growth retardation and low birth weight [58]. It
might even exacerbate the sometimes fatal effects of malaria
infection in infants and young children.
4) Treating STH infections in women-of-child-bearing-age
improves both maternal health status and the status of infants
born to infection-free mothers; therefore, WHO recommends
that anthelminthic treatment be included in strategies to
improvematernalnutritionwhereverhookworminfectionand
anemia are prevalent [30]. (GPELF, however, currently
restricts its treatment to women who are not pregnant.)
In addition to its effect on certain of the STH infections,
ivermectin – as GPELF’s second drug with broad-spectrum anti-
parasite activity – is unsurpassed for the oral treatment of both
onchocerciasis [34] and ectoparasites (scabies and lice) [31]. While
ivermectin has been the mainstay of onchocerciasis control
programs for the past 2 decades, the control programs in Africa
(where 99% of the onchocerciasis is found) have as their principal
target only communities designated hyper- or meso-endemic
(i.e., prevalence $40%), so that many communities endemic for
onchocerciasis were left untreated until GPELF was initiated [34].
Since LF is distributed very much more widely than onchocerci-
asis, and since almost all regions of Africa where onchocerciasis is
endemic are also ‘at risk’ for LF, GPELF activity in those areas has
resulted in the treatment of millions of additional individuals in
these onchocerciasis-endemic areas who were not covered under
the older control programs. These individuals are generally not
those with blinding onchocerciasis but with severe onchocercal
skin disease (OSD) and ‘‘troublesome itching’’; the burden of
illness from this OSD, quantified in DALYS lost, is recognized as
essentially equivalent to that estimated for onchocercal ocular
disease and blindness [33]. GPELF’s impact on improving OSD is
not yet quantified, but it can be defined once the number of
individuals with onchocerciasis who live in the expanded
treatment areas is more well understood [34]. On the other hand,
for the very important skin diseases caused by scabies and lice, the
significant health benefits that GPELF brings through its use of
ivermectin in affected populations will be much more difficult to
quantify, since so much less is known about the epidemiology of
these widespread ectoparasite diseases, and no burden-of-illness
estimates have yet been established [32].
The Global Programme to Eliminate LF is not a static program;
indeed, its reach continues to expand each year. In 2008 it is
projected that .500 million people will be treated in that year
alone. The effect on the calculated health benefits of the Programme
that these progressively increasing numbers will have each year is
enormous, since the number of protected children and cases of
disease prevented will increase rapidly as new cohorts of treated
individuals are added each year; in addition, of course, all of those
benefits not currently quantified (both LF-related and beyond-LF
effects) will continue to multiply as well.
Already the GPELF has been described as a ‘best buy’ in global
health, and the present tally of health benefits only strengthens this
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treatments have been given and 32 million DALYs-averted have
been identified by considering (conservatively) just 2 of the 5 specific
impacts attributable to the Programme (Tables 2 & 3). Considering
only these DALYs and estimating treatment costs at $0.10/person (a
‘high’ estimate given the fact that the preponderance of treatments
were in countries where costs have been identified as being much
lower [59]) suggests that, excluding the donated drug costs, $190
million will have been spent to effect the 1.9 billion treatments. If the
32 million averted DALYs were the only benefits achieved, each
DALY averted by the Programme would have cost $5.90. This cost
isextremelylow compared to DALYavertedcosts ofotherprograms
[60], but even it is a gross overestimate of the true cost of DALYs-
averted by GPELF activities, since so much of the Programme’s
benefit (Tables 2 & 3) remain unquantified and not included in this
calculation. Asthis LFElimination Programmecontinues toexpand,
its benefits will continue to accrue; as our ability to quantify these
benefits improves, the Programme’s true value will become
progressively still more impressive.
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